Brief: Newron And EA Pharma Announce License Agreement For Evenamide In Japan And Other Asian Territories
13/12/2024 12:34
Dec 13 (Reuters) - Newron Pharmaceuticals SpA NWRN.S :
* NEWRON AND EA PHARMA (A SUBSIDIARY OF EISAI CO., LTD.)
ANNOUNCE
LICENSE AGREEMENT FOR EVENAMIDE IN JAPAN AND OTHER ASIAN
TERRITORIES
* NEWRON PHARMACEUTICALS SPA - TO RECEIVE UP TO €117 MILLION
FROM
EA PHARMA
* NEWRON PHARMACEUTICALS SPA - TO BEGIN PHASE III TRIAL FOR
EVENAMIDE IN H1 2025
Source text: ID:nBw14y3vNa
Further company coverage: NWRN.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study